Concordance between the updated Elecsys cerebrospinal fluid immunoassays and amyloid positron emission tomography for Alzheimer's disease assessment: findings from the Apollo study.

• Tác giả: Margherita Carboni, Magnus Förnvik Jonsson, Stefanie Gaupp, Mayme Gummesson, Ekaterina Manuilova, Silja McIlwrick, Rikard Nilsson, Sandra Rutz, Henrik Schinke, Erik Stomrud, Jan-Philipp Weinberger
• Ngôn ngữ: eng
• Thông tin xuất bản: Germany : Clinical chemistry and laboratory medicine , 2025
• Bộ sưu tập: NCBI
• ID: 695909

Tóm tắt

OBJECTIVES: The Apollo study was designed to support the clinical performance verification of the adjusted cutoffs of the Elecsys METHODS: The primary study endpoint was to assess the concordance of the Elecsys CSF ratios and Aβ RESULTS: Of 108 screened individuals, 91 met the eligibility criteria, of whom 44.0 % were amyloid PET-positive and 56.0 % amyloid PET-negative. Positive percent agreement (PPA) and negative percent agreement, respectively, were 0.800 and 0.882 for pTau/Aβ CONCLUSIONS: Elecsys CSF ratios and Aβ